Literature DB >> 18498274

Study of the applicabilty of content uniformity and dissolution variation test on ropinirole hydrochloride tablets.

Edina Vranić1, Alija Uzunović.   

Abstract

When considering single-dose preparations, it is fundamental that the patient receives in his individual dose an amount of drug close to that claimed on the label. Since drug content and content uniformity of single-dose preparations depend on a number of processes associated with their manufacture, it is obviously unrealistic to expect every unit of product to possess exactly the same amount of the active ingredient. For that reason, pharmacopeial standards and specifications have been established to provide limits for permissible variations in the amount of active ingredient of individual single-dose units. The aim of our study was to determine the applicability of content uniformity and dissolution variation test on ropinirole hydrochloride tablets. According to the results obtained, we may conclude that analyzed ropinirole hydrochloride tablets satisfied pharmacopeial requirements concerning content uniformity and dissolution testing. In this case RSD tended to increase with the decrease of the labeled strength. It is obvious from the R2 value, as well. On the other side, if consider larger number of lots, analyzed by different assay methods and various sample preparation procedures this correlation is less pronounced. This may be a consequence of different assay techniques applied, HPLC, UV-D1 or UV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498274      PMCID: PMC5698354          DOI: 10.17305/bjbms.2008.2981

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  8 in total

1.  Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.

Authors:  R L Williams; W Adams; M L Chen; D Hare; A Hussain; L Lesko; R Patnaik; V Shah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

Review 2.  Content uniformity and dose uniformity: current approaches, statistical analyses, and presentation of an alternative approach, with special reference to oral inhalation and nasal drug products.

Authors:  Roger L Williams; Wallace P Adams; Guirag Poochikian; Walter W Hauck
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

3.  Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content.

Authors:  W W Hauck; R Shaikh
Journal:  J Biopharm Stat       Date:  2001-11       Impact factor: 1.051

4.  International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice.

Authors: 
Journal:  Fed Regist       Date:  2000-12-29

5.  Uniformity of dosage units--comparative study of methods and specifications between Eur. Pharm. 3rd and USP 23.

Authors:  J M Martins; A Farinha
Journal:  J Pharm Biomed Anal       Date:  1998-12       Impact factor: 3.935

6.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

7.  Statistics: the problem of examining accumulating data more than once.

Authors:  K McPherson
Journal:  N Engl J Med       Date:  1974-02-28       Impact factor: 91.245

Review 8.  Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.

Authors:  J D Esinhart; V M Chinchilli
Journal:  Int J Clin Pharmacol Ther       Date:  1994-01       Impact factor: 1.366

  8 in total
  1 in total

1.  Development of Atorvastatin Calcium Biloaded Capsules for Oral Administration of Hypercholesterolemia.

Authors:  Chitra Karthikeyini Senthilvel; Kavitha Karuppaiyan; Ananth Pothumani; Ananthi Vedharethinam; Ancy Wilfred Jose; Jamal Moideen Muthu Mohamed; Mohamed El Sherbiny; Hasnaa Ali Ebrahim; Mohamed El Shafey; Minilu Dejene
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-16       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.